Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent protects the company’s use of artificial intelligence (AI) and machine learning to analyze magnetic resonance spectroscopy (MRS) data for identifying the location of chronic low back pain.
The newly granted patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability aims to ensure consistent, reproducible outputs across different imaging systems and clinical sites, which is a critical step toward broader clinical adoption.
Aclarion’s cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The patent strengthens the company’s ability to scale by protecting its use of AI in future versions of the platform, further automating biomarker identification, accelerating report generation, and reducing manual quality reviews. According to the company, this positions Aclarion to enhance its already strong gross margins while expanding its market reach.
“This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice,” said Brent Ness, Chief Executive Officer of Aclarion. “By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent expands Aclarion’s intellectual property portfolio to 64 issued and pending patents worldwide, reinforcing the company’s long-term competitive moat. The chronic low back pain market remains large and underserved, affecting approximately 266 million people globally. Clinical data suggests that when used alongside other diagnostic tools, Nociscan can achieve up to a 97% surgical success rate when all Nociscan-positive discs are treated.
The full patent is available for review here. For more information about Aclarion and Nociscan, visit the company’s website or view the latest news here.
